$93.87
0.30% yesterday
Nasdaq, Nov 25, 10:00 pm CET
ISIN
US09627Y1091
Symbol
BPMC
Sector
Industry

Blueprint Medicines Corp. Stock price

$93.87
+11.40 13.82% 1M
-8.94 8.70% 6M
+1.63 1.77% YTD
+24.75 35.81% 1Y
-10.42 9.99% 3Y
+15.01 19.03% 5Y
+75.00 397.46% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
-0.28 0.30%
ISIN
US09627Y1091
Symbol
BPMC
Sector
Industry

Key metrics

Market capitalization $5.96b
Enterprise Value $5.96b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 13.72
P/S ratio (TTM) P/S ratio 13.73
P/B ratio (TTM) P/B ratio 19.02
Revenue growth (TTM) Revenue growth 100.93%
Revenue (TTM) Revenue $434.41m
EBIT (operating result TTM) EBIT $-275.95m
Free Cash Flow (TTM) Free Cash Flow $-250.52m
Cash position $734.17m
EPS (TTM) EPS $-2.11
P/E forward negative
P/S forward 11.72
EV/Sales forward 11.71
Short interest 7.33%
Show more

Is Blueprint Medicines Corp. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Blueprint Medicines Corp. Stock Analysis

Unlock Scores for Free

Analyst Opinions

20 Analysts have issued a Blueprint Medicines Corp. forecast:

14x Buy
70%
5x Hold
25%
1x Sell
5%

Analyst Opinions

20 Analysts have issued a Blueprint Medicines Corp. forecast:

Buy
70%
Hold
25%
Sell
5%

Financial data from Blueprint Medicines Corp.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
434 434
101% 101%
100%
- Direct Costs 27 27
41% 41%
6%
408 408
139% 139%
94%
- Selling and Administrative Expenses 328 328
35% 35%
76%
- Research and Development Expense 341 341
21% 21%
79%
-262 -262
48% 48%
-60%
- Depreciation and Amortization 14 14
47% 47%
3%
EBIT (Operating Income) EBIT -276 -276
48% 48%
-64%
Net Profit -128 -128
77% 77%
-29%

In millions USD.

Don't miss a Thing! We will send you all news about Blueprint Medicines Corp. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Blueprint Medicines Corp. Stock News

Positive
Seeking Alpha
11 days ago
Blueprint Medicines' core revenue driver, AYVAKIT, has gained traction in systemic mastocytosis and gastrointestinal stromal tumors, reflecting strong market adoption. The recent AYVAKIT expansion into Germany and the potential for further indication of growth underpin Blueprint's valuation and future revenue projections. Blueprint's investigational pipeline, including drugs like BLU-222 and el...
Neutral
Seeking Alpha
27 days ago
Blueprint Medicines Corporation (NASDAQ:BPMC ) Q3 2024 Earnings Conference Call October 30, 2024 8:00 AM ET Company Participants Jenna Cohen - Vice President-Investor Relations Kate Haviland - Chief Executive Officer Philina Lee - Chief Commercial Officer Christy Rossi - Chief Operating Officer Mike Landsittel - Chief Financial Officer Fouad Namouni - President-Research & Development Conference...
Neutral
PRNewsWire
27 days ago
-- Achieved $128.2 million in AYVAKIT net product revenues in the third quarter 2024 -- -- Raising AYVAKIT net product revenue guidance to $475 million to $480 million for 2024 -- --  On track to initiate the registration-enabling HARBOR Part 2 study of elenestinib in ISM by year end -- CAMBRIDGE, Mass. , Oct. 30, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today reporte...
More Blueprint Medicines Corp. News

Company Profile

Blueprint Medicines Corp. is a precision therapy company. It focuses on medicines to improve the lives of patients with genomically defined cancers, rare diseases and cancer immunotherapy. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA.

Head office United States
CEO Kathryn Haviland
Employees 655
Founded 2008
Website www.blueprintmedicines.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today